A detailed history of Assenagon Asset Management S.A. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 311,643 shares of VRTX stock, worth $124 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
311,643
Previous 96,195 223.97%
Holding current value
$124 Million
Previous $45.1 Million 221.46%
% of portfolio
0.3%
Previous 0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$460.0 - $505.78 $99.1 Million - $109 Million
215,448 Added 223.97%
311,643 $145 Million
Q2 2024

Jul 18, 2024

SELL
$392.81 - $485.53 $89.1 Million - $110 Million
-226,893 Reduced 70.23%
96,195 $45.1 Million
Q1 2024

Apr 24, 2024

BUY
$407.69 - $446.08 $11 Million - $12 Million
26,935 Added 9.09%
323,088 $135 Million
Q4 2023

Jan 17, 2024

BUY
$343.0 - $410.68 $32.2 Million - $38.6 Million
93,922 Added 46.44%
296,153 $121 Million
Q3 2023

Nov 06, 2023

SELL
$338.18 - $362.46 $61.7 Million - $66.1 Million
-182,487 Reduced 47.43%
202,231 $70.3 Million
Q2 2023

Jul 25, 2023

SELL
$314.42 - $351.91 $73.6 Million - $82.4 Million
-234,078 Reduced 37.83%
384,718 $135 Million
Q1 2023

Apr 18, 2023

SELL
$283.23 - $323.1 $34 Million - $38.8 Million
-120,191 Reduced 16.26%
618,796 $195 Million
Q4 2022

Jan 12, 2023

BUY
$285.76 - $321.48 $21.9 Million - $24.7 Million
76,752 Added 11.59%
738,987 $213 Million
Q3 2022

Oct 27, 2022

BUY
$273.83 - $305.53 $40 Million - $44.7 Million
146,237 Added 28.34%
662,235 $192 Million
Q2 2022

Jul 27, 2022

SELL
$234.96 - $292.55 $68.7 Million - $85.6 Million
-292,556 Reduced 36.18%
515,998 $145 Million
Q1 2022

Apr 25, 2022

BUY
$221.42 - $260.97 $108 Million - $127 Million
486,323 Added 150.92%
808,554 $211 Million
Q4 2021

Feb 01, 2022

BUY
$177.01 - $223.45 $44.7 Million - $56.5 Million
252,752 Added 363.78%
322,231 $70.8 Million
Q3 2021

Oct 19, 2021

SELL
$181.39 - $202.99 $30.2 Million - $33.8 Million
-166,649 Reduced 70.58%
69,479 $12.6 Million
Q2 2021

Jul 15, 2021

SELL
$187.49 - $221.1 $7.06 Million - $8.32 Million
-37,631 Reduced 13.75%
236,128 $47.6 Million
Q1 2021

Apr 26, 2021

SELL
$207.02 - $241.31 $67.2 Million - $78.4 Million
-324,687 Reduced 54.26%
273,759 $58.8 Million
Q4 2020

Feb 01, 2021

BUY
$207.01 - $276.09 $98.1 Million - $131 Million
474,130 Added 381.39%
598,446 $141 Million
Q3 2020

Oct 07, 2020

SELL
$255.65 - $303.1 $335,924 - $398,273
-1,314 Reduced 1.05%
124,316 $33.8 Million
Q2 2020

Jul 21, 2020

SELL
$225.48 - $295.8 $145 Million - $190 Million
-641,941 Reduced 83.63%
125,630 $36.5 Million
Q1 2020

Apr 17, 2020

BUY
$199.77 - $247.81 $99.5 Million - $123 Million
498,163 Added 184.91%
767,571 $183 Million
Q4 2019

Jan 17, 2020

BUY
$166.71 - $223.91 $40.1 Million - $53.9 Million
240,816 Added 842.25%
269,408 $59 Million
Q3 2019

Oct 16, 2019

BUY
$166.23 - $187.09 $3.21 Million - $3.62 Million
19,333 Added 208.8%
28,592 $4.84 Million
Q2 2019

Aug 12, 2019

SELL
$164.61 - $190.37 $9.76 Million - $11.3 Million
-59,305 Reduced 86.5%
9,259 $1.7 Million
Q1 2019

Apr 26, 2019

SELL
$163.73 - $194.7 $51.6 Million - $61.4 Million
-315,198 Reduced 82.13%
68,564 $12.6 Million
Q4 2018

Jan 23, 2019

BUY
$151.91 - $192.21 $29.2 Million - $37 Million
192,494 Added 100.64%
383,762 $63.6 Million
Q3 2018

Oct 29, 2018

SELL
$167.73 - $192.74 $29.1 Million - $33.4 Million
-173,500 Reduced 47.56%
191,268 $36.9 Million
Q2 2018

Jul 17, 2018

BUY
$145.72 - $169.96 $31 Million - $36.1 Million
212,481 Added 139.53%
364,768 $62 Million
Q1 2018

Apr 30, 2018

SELL
$151.6 - $177.13 $953,109 - $1.11 Million
-6,287 Reduced 3.96%
152,287 $24.8 Million
Q4 2017

Jan 25, 2018

SELL
$137.28 - $155.55 $101 Million - $114 Million
-734,806 Reduced 82.25%
158,574 $23.8 Million
Q3 2017

Oct 18, 2017

BUY
$148.13 - $162.24 $132 Million - $145 Million
893,380
893,380 $136 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.